ArticleFrontiers in oncology2026
Case Report: Clinical analysis and literature review of two cases of high-grade adult-type cervical embryonal rhabdomyosarcoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Embryonal rhabdomyosarcoma (ERMS) predominantly occurs in children; primary cervical ERMS in adults is exceedingly rare and readily misdiagnosed, as its typical presentations-abnormal vaginal bleeding and a cervical mass-closely resemble gestational trophoblastic disease and uterine sarcomas. Case report: We present two cases of high-grade cervical ERMS in reproductive-age women; both presented \with abnormal vaginal bleeding and were diagnosed with stage IVB disease with regional lymph node metastasis at initial admission. Case 1 was complicated by synchronous bilateral pulmonary and multiple osseous metastases, while Case 2 exhibited a massive cervical tumor with extensive lymphatic dissemination. The two patients received distinct multimodal treatment regimens: one underwent primary surgery followed by adjuvant chemotherapy; the other received interventional embolization, neoadjuvant chemotherapy, radical resection, sequential chemoradiotherapy, and exploratory targeted maintenance therapy. Conclusion: Adult cervical ERMS is highly aggressive and prone to early distant spread. Immunohistochemical markers are mandatory to confirm the rhabdomyogenic origin of this tumor. For patients with advanced disease, multimodal regimens combining neoadjuvant chemotherapy, radical resection (when surgically feasible), and adjuvant chemoradiotherapy may serve as a primary comprehensive approach to potentially prolong overall survival. In patients with actionable somatic alterations identified through comprehensive molecular profiling and formal HRD testing, individualized exploratory targeted therapy may be explored only in highly selected patients. Further clinical investigations are warranted to refine treatment strategies and improve long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.